PITTSBURGH, Oct. 2 /CNW/ -- Mylan Inc. (NYSE: MYL) today announced the
appointment of Rajiv Malik as Executive Vice President in charge of Global
Technical Operations. Mr. Malik has served in a similar capacity for Mylan
since the Company acquired a controlling stake in Matrix Laboratories Limited
(Matrix), where he is Chief Executive Officer, in January 2007.
As Head of Global Technical Operations, Mr. Malik will oversee the
Company's global research and development (R&D) centers and manufacturing and
distribution units, with responsibility for enhancing and rationalizing
Mylan's global supply chain and expanded product pipeline, as well as
leveraging Matrix, one of the world's largest suppliers of active
pharmaceutical ingredients, across the enlarged company.
Mr. Malik has worked more than 24 years in the global generic
pharmaceutical industry. In addition to his role at Mylan, Mr. Malik
currently serves as Managing Director and Chief Executive Officer of Matrix.
Prior to joining Matrix in 2005, he was Head of Global Development and
Regulatory at Sandoz. He started his career in R&D at Ranbaxy Laboratories,
rising to Head of Generics R&D.
Mylan's Vice Chairman and CEO Robert J. Coury commented, "Rajiv has been
an invaluable addition to the Mylan management team since joining us in
January. Since the close of the Matrix transaction, he has truly proven his
capabilities and has been instrumental in the successful integration of
Matrix. Rajiv has built an outstanding operational infrastructure that will
allow us to capitalize on the efficiencies, synergies and sourcing
opportunities we see from bringing together all three companies."
Mr. Malik earned his master's degree in pharmaceutical technology from
Punjab University and has more than 60 process patents to his credit.
Mylan Inc. is one of the world's leading quality generic and specialty
pharmaceutical companies. The Company offers one of the industry's broadest
and highest quality product portfolios, a robust product pipeline and a global
commercial footprint through operations in more than 90 countries. Through
its controlling interest in Matrix Laboratories Limited, Mylan has direct
access to one of the largest active pharmaceutical ingredient (API)
manufacturers in the world. Dey L.P., Mylan's fully integrated specialty
business, provides the Company with innovative and diversified opportunities
in the respiratory and allergy therapeutic areas.
For more information about Mylan, please visit www.mylan.com.
For further information:
For further information: Kris King, Mylan Inc., +1-724-514-1800 Web